Pieris Pharmaceuticals is a biopharmaceutical company that has made significant strides in the discovery and development of Anticalin-based drugs to target validated disease pathways. The company’s journey has been marked by both successes and challenges, as it navigates the ever-evolving landscape of the pharmaceutical industry.
Company Background
Founded in 2001 as Pieris AG in Germany, the company underwent a significant transformation in May 2013 with the establishment of Pieris Pharmaceuticals, Inc. In December 2014, Pieris Pharmaceuticals, Inc. acquired a 100% interest in Pieris AG, which was then renamed Pieris Pharmaceuticals GmbH. This acquisition marked a pivotal moment in the company’s history, consolidating its operations and setting the stage for future growth.
The company’s proprietary Anticalin technology platform, developed in Germany, has served as the foundation for its diverse pipeline of drug candidates, targeting a range of therapeutic areas, including immuno-oncology (IO) and respiratory diseases. This innovative platform has been instrumental in attracting partnerships with major pharmaceutical companies.
Strategic Partnerships and Developments
In 2017, Pieris entered into a series of collaboration agreements with industry giants such as AstraZeneca, Servier, Pfizer (formerly Seagen), and Genentech. These partnerships were aimed at advancing Pieris’ Anticalin-based drug candidates and provided valuable validation for the company’s technology. However, over time, the majority of these programs were discontinued or terminated by the partners, reflecting the challenging nature of drug development.
One of the key highlights in Pieris’ history was the advancement of its IO bispecific drug candidates, such as SGN-BB228 and BOS-342.00, which are currently in clinical development with Pieris’ partners. These programs have demonstrated promising results, with the company potentially eligible for up to approximately $15 million in milestones upon first patient dosed in the Phase 2 trials, and up to approximately $40 million in milestones upon first patient dosed in pivotal clinical trials.
Challenges and Strategic Shifts
However, the company has also faced significant challenges, particularly in 2023. The discontinuation of its inhaled respiratory program, elarekibep, following AstraZeneca’s decision to terminate the collaboration agreement, was a major setback. This event triggered a series of strategic decisions aimed at reshaping the company’s future.
In July 2023, Pieris announced its intention to explore strategic transactions, including mergers, reverse mergers, acquisitions, and other business combinations or asset sales. To facilitate this process, the company engaged Stifel, Nicolaus & Company, Incorporated as its strategic advisor. Concurrently, Pieris implemented a significant workforce reduction, cutting approximately 70% of its employees.
The company continued to take steps to reduce its operating footprint throughout 2023 and into 2024. This included terminating its remaining lease obligations in Germany, winding down its proprietary inhaled respiratory programs, and opting out of programs where possible to reduce operating costs. Further workforce reductions were implemented as a result of these actions.
By the end of 2023, Pieris had satisfied all of its remaining obligations under its previous collaborations. The company’s focus shifted to maximizing the potential milestone and royalty payments from the remaining partnered programs with Pfizer and Boston Pharmaceuticals.
New Strategic Direction
In March 2024, Pieris announced a new strategic direction, aimed at extending its cash runway into at least 2027 while capitalizing on the milestones from its partnered 4-1BB bispecific Mabcalin protein IO assets. This strategic pivot, coupled with significant workforce reductions and the termination of all internal research and development activities, has positioned the company to navigate the challenges it faces and potentially unlock the value of its remaining assets.
Financials and Liquidity
As of September 30, 2024, Pieris reported a total of $19.36 million in cash and cash equivalents, with net losses of $2.89 million and $11.37 million for the three and nine months ended September 30, 2024, respectively. The company’s balance sheet reflects its efforts to preserve cash, as it has significantly reduced its operating expenses and shifted its focus to its partnered programs.
For the most recent quarter (Q3 2024), Pieris reported no revenue, a net loss of $2.89 million, and operating cash flow (OCF) of $146,000. The free cash flow (FCF) for the same period was also $146,000. The company’s financial position is further characterized by a debt-to-equity ratio of 0, a current ratio of 4.82, and a quick ratio of 4.82.
Pieris’s liquidity position remains stable, with $19.36 million in cash and cash equivalents as of September 30, 2024. The company does not appear to have any available credit facilities or credit lines disclosed. This financial position, combined with the company’s strategic shift to focus on partnered programs, is expected to extend its cash runway into at least 2027.
Product Segments and Pipeline
Pieris’s clinical pipeline now consists primarily of IO bispecific programs partnered with major pharmaceutical companies. The key assets include:
BOS-342 (PRS-342): Targeting GPC3 and 4-1BB, this asset is being developed by Boston Pharmaceuticals. In August 2023, the first patient was dosed in a Boston Pharmaceuticals-sponsored Phase 1/2 study for hepatocellular carcinoma, resulting in a $2.5 million milestone payment to Pieris.
Pieris has discontinued its proprietary respiratory programs, including PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor (CTGF) for idiopathic pulmonary fibrosis and other fibrotic lung diseases. The company completed a Phase 1 study of PRS-220 in healthy volunteers in August 2023 but decided to discontinue further development for strategic and scientific reasons.
The partnership with AstraZeneca for elarekibep (PRS-060/AZD1402), an inhaled IL-4Rα antagonist Anticalin protein for uncontrolled asthma, was terminated in October 2023 following AstraZeneca’s decision to discontinue clinical studies based on non-clinical safety findings.
Future Outlook and Challenges
Looking ahead, Pieris’ future will be largely shaped by the progress and success of its IO bispecific assets in development with Pfizer and Boston Pharmaceuticals. The potential for significant milestone payments, as well as future royalties, could provide a crucial lifeline for the company as it navigates the next chapter of its evolution.
However, the company is also facing potential risks, including the ongoing pandemic and geopolitical tensions, which could impact the timelines and progress of its partnered programs. Additionally, the company’s status as a smaller reporting company, with the associated reduced disclosure and compliance requirements, may pose challenges in attracting investor attention and maintaining market confidence.
Despite these hurdles, Pieris remains committed to its mission of developing innovative therapies that address unmet medical needs. The company’s resilience and its ability to adapt to changing market conditions will be critical in determining its long-term success.
Recent Developments
On March 27, 2024, Pieris announced the implementation of a new strategy along with relevant cost-saving measures. This strategic shift is expected to extend the company’s cash runway into at least 2027 while maximizing its ability to capture potential milestones from its partnered 4-1BB bispecific Mabcalin protein IO assets.
In a significant development, on July 23, 2024, Pieris entered into a definitive merger agreement with Palvella Therapeutics, Inc. This transaction is expected to close in the fourth quarter of 2024, subject to stockholder approval. This merger represents a potential turning point for Pieris, potentially providing new opportunities and resources to advance its strategic objectives.
Conclusion
In conclusion, Pieris Pharmaceuticals has demonstrated its ability to navigate the complexities of the biopharmaceutical industry, leveraging its proprietary Anticalin technology and strategic partnerships to advance its drug pipeline. As the company embarks on its new strategic path, investors will be closely watching the progress of its partnered programs and the company’s ability to monetize its remaining assets, while addressing the challenges that lie ahead. The upcoming merger with Palvella Therapeutics and the potential milestone payments from its partnered programs offer promising avenues for Pieris to create value and potentially return to a growth trajectory in the coming years.
Disclaimer: This article is for informational purposes only. It does not constitute financial, legal, or other types of advice. While every effort has been made to ensure the accuracy of the information presented here, the author and the publisher do not make any guarantees about the completeness, reliability, and accuracy of this information.